As communicated on 21 December 2015, Actelion has obtained the FDA approval for Selexipag (Uptravi, an oral selective prostacyclin IP receptor agonist). The group held a conference call on 5 January to discuss the approval and market opportunities.
05 Jan 2016
After the FDA approval of Selexipag
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
After the FDA approval of Selexipag
As communicated on 21 December 2015, Actelion has obtained the FDA approval for Selexipag (Uptravi, an oral selective prostacyclin IP receptor agonist). The group held a conference call on 5 January to discuss the approval and market opportunities.